


Form PTO-1449 (Rev. 8-88)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. C-3169/1/US	Serial No. 09/451,641
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant Gao, D. et al.	
				Filing Date November 30, 1999	Group No. 1614



U.S. PATENT DOCUMENTS							
Examiner Initial*	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate	
S.T.	AA	5,760,068	Talley et al	514	403		
S.T.	AB	5,466,823	Talley et al	548	377.1		

FOREIGN PATENT DOCUMENTS							
Examiner Initial*	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
S.T.	BA	0 863 134	EPO EP	C07C	317/24		x
S.T.	BB	96/37476	WIPO WO	C07D	231/12		x

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)		
S.T.	CA	Lipsky & Isakson (1997). Outcome of specific COX-2 inhibition in rheumatoid arthritis. Journal of Rheumatology 24 (Supp. 49), 9-14.
S.T.	CB	Penning et al. (1997). Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). Journal of Medicinal Chemistry 40, 1347-1365.
S.T.	CC	Simon et al. (1998). Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor. Arthritis & Rheumatism 41, 1591-1602.

Examiner S.T.	Date Considered 01/04/01
-------------------------	------------------------------------

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.